Hasil Pencarian - Ian Walters

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients

    411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractor... oleh Lilian Siu, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Nilofer Azad, Lewis Bender, Ian Walters, Giles Whalen, Matthew Ingham

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

    712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell... oleh David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.

    Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. oleh Ikuo Nakamura, Kais Zakharia, Bubu A Banini, Dalia S Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D Moser, Hassan M Shaleh, Sarah R Thornburgh, Ian Walters, Lewis R Roberts

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    536 Intratumoral INT230–6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with ipilimumab [Intensity IT-01; BMS#CA184–592]

    536 Intratumoral INT230–6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with ipilimumab [Intensit... oleh Anthony Olszanski, Lilian Siu, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Nilofer Azad, Lewis Bender, Ian Walters, Giles Whalen, Matthew Ingham, Christian Meyer, James Hu, Syed Mahmood, Albiruni Razak

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling.

    Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. oleh Ikuo Nakamura, Kais Zakharia, Bubu A Banini, Dalia S Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D Moser, Hassan M Shaleh, Sarah R Thornburgh, Ian Walters, Lewis R Roberts

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

    Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory oleh Anja C. Bloom, Lewis H. Bender, Shweta Tiwary, Lise Pasquet, Katharine Clark, Tianbo Jiang, Zheng Xia, Aizea Morales-Kastresana, Jennifer C. Jones, Ian Walters, Masaki Terabe, Jay A. Berzofsky

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

    Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-labe... oleh Mark R Middleton, Winald R Gerritsen, Ian Walters, Licia Rivoltini, Niven Mehra, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Uzi Gileadi, Inka Pawlitzky, Konstantina Grosios, Petronella B Ottevanger

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors oleh Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: